As President of DIAXONHIT's Management Board since June 2017, Jean-Michel Carle Grandmougin is in charge of the group's marketing and sales strategy, quality and regulatory issues, as well as sales in France.

Jean-Michel Carle Grandmougin has more than 32 years of experience in the field of in vitro diagnostics and research in life sciences. Before becoming a member of the Management Board of the DIAXONHIT Group, he was Chairman and Chief Executive Officer and one of the two partners of the EUROBIO / Capforce Group which was acquired by DIAXONHIT in March 2017. He joined EUROBIO SA in 2006 as Sales Manager and quickly became its Managing Director. In June 2010, he acquired the company with Denis Fortier and the OTC Asset Management fund which sold back its shares in 2014 to Jean-Michel and Denis. In 1992, he joined BMD (now Theradiag) where he was Sales Director for 13 years before taking responsibility of its German activity. Holder of a bachelor's degree in biology, he began his career in 1985 at Technicon (now Bayer Diagnostics) as a Technical Sales Engineer to become Sales Manager at 30. Jean-Michel Carle Grandmougin owns approximately 17% of DIAXONHIT.